With 82.85 million shares changed hands, the volume of the stock remained lighter than its average volume of 100.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.3439 whereas the lowest price it dropped to was $0.3068. The 52-week range on TNXP shows that it touched its highest point at $12.61 and its lowest point at $0.12 during that stretch. It currently has a 1-year price target of $3.25. Beta for the stock currently stands at 2.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TNXP was down-trending over the past week, with a drop of -7.43%, but this was up by 79.60% over a month. Three-month performance surged to 124.18% while six-month performance fell -56.13%. The stock lost -97.42% in the past year, while it has lost -5.25% so far this year. A look at the trailing 12-month EPS for TNXP yields -20.56 with Next year EPS estimates of -0.62. For the next quarter, that number is -0.18. This implies an EPS growth rate of 95.88% for this year and 45.37% for next year.
Float and Shares Shorts:
At present, 186.89 million TNXP shares are outstanding with a float of 186.89 million shares on hand for trading. On 2024-10-31, short shares totaled 7.67 million, which was 548.0 higher than short shares on 1727654400. In addition to Dr. Seth Lederman M.D. as the firm’s Co-Founder, President, CEO & Chairman, Mr. Bradley Saenger CPA serves as its CFO & Treasurer.
Institutional Ownership:
Through their ownership of 0.00228 of TNXP’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, TNXP reported revenue of $2822000.0 and operating income of -$13886000.0. The EBITDA in the recently reported quarter was -$13376000.0 and diluted EPS was -$0.23.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TNXP since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TNXP analysts setting a high price target of 11.0 and a low target of 2.5, the average target price over the next 12 months is 5.83333. Based on these targets, TNXP could surge 3448.39% to reach the target high and rise by 706.45% to reach the target low. Reaching the average price target will result in a growth of 1781.72% from current levels.
Analysts have provided yearly estimates in a range of -$0.07467952 being high and -$2.19468 being low. For TNXP, this leads to a yearly average estimate of -$1.135.
